---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063021"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:44:48.515710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma Q3 2023: Revenue $16.9M, cash runway into H1 2025; luvelta data and new CSO

## Summary
- Cash and investments $321.1M plus Vaxcyte shares valued at $34.0M projecting runway into first half 2025.
- Q3 2023 revenue $16.9M, down from $25.1M in Q3 2022; operating expenses $60.9M vs $46.4M.
- Luvelta showed encouraging anti-tumor activity in FolRα-selected endometrial cancer at ESMO 2023; AML compassionate use data at ASH 2023.
- Dr. Hans-Peter Gerber appointed Chief Scientific Officer in September 2023.
- REFRaME-O1 Phase 2/3 trial for platinum-resistant ovarian cancer enrollment underway; global registration discussions with FDA/EMA.

## SEC filing metadata
- accession: 0000950170-23-063021
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/stro-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063021
- JSON: https://secwatch.observer/filing/0000950170-23-063021.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063021.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported financial results for the third quarter of 2023.
  - Period: the third quarter of 2023
  - Result: reported results
  source text: On November 13, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.